H1N1 Puerto Rico Recombinant
Description
Recombinant Full-Length H1N1 Puerto Rico 08/1934 is glycosylated with N-linked sugars, produced using baculovirus vectors in insect cells and its Mw is approximately 62 kDa.
Product Specs
Product Science Overview
The H1N1 Influenza A virus, specifically the Puerto Rico 08/1934 strain, is a significant historical and scientific entity in the study of influenza viruses. This strain has been extensively used in research due to its well-documented genetic and antigenic properties. The recombinant form of this virus, particularly the hemagglutinin (HA) protein, has been instrumental in understanding viral mechanisms and developing vaccines.
The Puerto Rico 08/1934 strain of H1N1 Influenza A virus was first isolated in 1934. This strain is one of the earliest and most well-characterized influenza viruses. It has served as a reference strain in numerous studies and has been pivotal in the development of influenza vaccines. The 1934 strain is particularly notable for its role in the 1918 influenza pandemic, which caused widespread morbidity and mortality globally.
The H1N1 Influenza A virus has a segmented RNA genome, which allows for genetic reassortment and the emergence of new viral strains. The Puerto Rico 08/1934 strain is characterized by its hemagglutinin (HA) and neuraminidase (NA) surface proteins. The HA protein facilitates viral entry into host cells by binding to sialic acid receptors, while the NA protein aids in the release of newly formed viral particles from infected cells.
The recombinant form of the Puerto Rico 08/1934 strain typically involves the expression of the HA protein in a host system, such as HEK293 cells. This recombinant HA protein is often tagged with a His-tag to facilitate purification and detection. The recombinant HA protein retains the antigenic properties of the native virus, making it a valuable tool for immunological studies and vaccine development .
The recombinant HA protein from the Puerto Rico 08/1934 strain has been widely used in various research applications, including:
- Vaccine Development: The HA protein is a primary target for influenza vaccines. Recombinant HA proteins are used to generate immune responses in vaccine candidates.
- Immunological Studies: Researchers use recombinant HA proteins to study the immune response to influenza infection and to identify potential therapeutic targets.
- Diagnostic Assays: Recombinant HA proteins are used in diagnostic assays to detect antibodies against influenza viruses in clinical samples.
